Delving into the Latest Updates on Synokem Pharmaceuticals Ltd. with Synapse

A phase III double blind multicenter randomized prospective parallel group study to evaluate the efficacy and safety of test product fixed dose combination of Gabapentin 200 mg and Duloxetine 20 mg capsule and test product fixed dose combination of Gabapentin 300 mg and Duloxetine 30 mg capsule manufactured by Synokem Pharmaceuticals Limited New Delhi India when compared with the reference product fixed dose combination of Pregabalin 75 mg and Duloxetine 30 mg capsule in treatment of neuropathic pain - NIL

开始日期2024-08-12

申办/合作机构

Synokem Pharmaceuticals Ltd.

CTRI/2024/03/064846 / Not yet recruitingN/A

A Multi-centric, Open label, Randomized, Non-Comparative, Two-Arm, Phase IV clinical trial to evaluate the safety and efficacy of Imeglimin 500 mg and 1000 mg tablets in the treatment of patients diagnosed with type-II diabetes mellitus in adequate control of diet and exercise alone. - IME

开始日期2024-04-10

申办/合作机构

Synokem Pharmaceuticals Ltd.

CTRI/2024/03/063691 / Temporarily not available临床3期

A Multicentric, Randomized, Double Blind, Double Dummy, Active Controlled, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Pregabalin, Duloxetine (As Gastro Resistant Pellets) and Mecobalamin Capsules Versus Fixed Dose Combination of Pregabalin, Nortriptyline and Mecobalamin Tablets for the Treatment of Patients with Diabetic Peripheral Neuropathic Pain with Coexistent Vitamin B12 Deficiency. - NIL

开始日期2024-03-25

申办/合作机构

Synokem Pharmaceuticals Ltd.

100 项与 Synokem Pharmaceuticals Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Synokem Pharmaceuticals Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Synokem Pharmaceuticals Ltd. 相关的新闻（医药）

2023-11-27

·SYNAPSE

Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB.

Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB (publ) on November 28, 2023. Abhijit Joshi,Tushar Raut, Anamika and Sameeksha Shetty of Veritas Legal advised Recipharma AB on the transaction. Pioneer legal advised Synokem Pharmaceuticals Limited in the transaction. Synokem Pharmaceuticals Limited completed the acquisition of 74% stake in Nitin Lifesciences Limited from Recipharm AB (publ) on November 28, 2023.

并购

100 项与 Synokem Pharmaceuticals Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Synokem Pharmaceuticals Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿折地平/替米沙坦 ( AT1R x L-type calcium channel )	高血压更多	临床阶段不明
阿齐沙坦酯/西尼地平 ( AT1R x VDCCs )	高血压更多	无进展
阿齐沙坦酯钾盐/氯噻酮 ( AT1R x NCC )	高血压更多	无进展